Safety of favipiravir for treatment of COVID-19: latest systematic review
Jurnal Respirologi Indonesia
; 42(1):67-75, 2022.
Article
in English
| GIM | ID: covidwho-1989879
ABSTRACT
Background:
Adverse event studies of favipiravir used to treat COVID-19 have been ongoing since it was established as a treatment option. A better understanding of the side effects of favipiravir from recent studies is important for developing and assessing the introduction of effective treatments for COVID-19.Method:
The author conducted a systematic review based on research studies and case reports on favipiravir monotherapy in COVID-19. Access to the included studies is via PubMed, SCOPUS, Science Direct, SpringerLink, and MedRxiv.
259793-96-9; 69-93-2; human diseases; coronavirus disease 2019; viral diseases; pandemics; public health; safety; drug therapy; favipiravir; systematic reviews; literature reviews; adverse effects; medical treatment; efficacy; case reports; clinical aspects; diarrhoea; liver; enzymes; hyperuricaemia; fever; viral load; dosage; uric acid; antiviral agents; man; Severe acute respiratory syndrome coronavirus 2; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; SARS-CoV-2; viral infections; chemotherapy; adverse reactions; clinical picture; diarrhea; scouring; hyperuricemia; pyrexia; antivirals
Search on Google
Collection:
Databases of international organizations
Database:
GIM
Type of study:
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
Jurnal Respirologi Indonesia
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS